title: Development of severe sclerotic chronic GVHD during treatment with dasatinib.
authors.forename: D
authors.initials: D
authors.lastname: Pulanic
authors.forename: E W
authors.initials: EW
authors.lastname: Cowen
authors.forename: K
authors.initials: K
authors.lastname: Baird
authors.forename: M R
authors.initials: MR
authors.lastname: Bishop
authors.forename: S Z
authors.initials: SZ
authors.lastname: Pavletic
mesh_terms: D002908:Chronic Disease; D003131:Combined Modality Therapy; D000069439:Dasatinib; D006086:Graft vs Host Disease / Q000209:etiology* / Q000473:pathology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*; D012598:Sclerosis; D012720:Severity of Illness Index; D013844:Thiazoles / Q000009:adverse effects*; D055815:Young Adult
chemical_list: D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000069439:Dasatinib